Predictors of recurrence, early treatment failure and death from Staphylococcus aureus bacteraemia: observational analyses within the ARREST trial
<br><strong>Objectives: </strong>Adjunctive rifampicin did not reduce failure/recurrence/death as a composite endpoint in the ARREST trial of Staphylococcus aureus bacteraemia, but did reduce recurrences. We investigated clinically-defined 14-day treatment failure, and recurrence a...
Prif Awduron: | Szubert, AJ, Bailey, SL, Cooke, GS, Peto, T, Llewelyn, MJ, Edgeworth, JD, Walker, AS, Thwaites, GE |
---|---|
Fformat: | Journal article |
Iaith: | English |
Cyhoeddwyd: |
Elsevier
2019
|
Eitemau Tebyg
-
Clinical management of Staphylococcus aureus bacteraemia.
gan: Thwaites, G, et al.
Cyhoeddwyd: (2011) -
Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT
gan: Thwaites, GE, et al.
Cyhoeddwyd: (2018) -
Rifampicin in treating S aureus bacteraemia - Authors' reply
gan: Thwaites, G, et al.
Cyhoeddwyd: (2018) -
Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial
gan: Thwaites, GE, et al.
Cyhoeddwyd: (2017) -
Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: the ARREST RCT
gan: Guy E Thwaites, et al.
Cyhoeddwyd: (2018-10-01)